Myriad Genetics (MYGN) Other Operating Expenses (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Other Operating Expenses data on file, last reported at $79.0 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $79.0 million, up 14.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $610.0 million (up 90.98% YoY), and the FY2025 annual result was $600.2 million, up 87.8% from the prior year.
• Other Operating Expenses grew to $79.0 million in Q1 2026 per MYGN's latest filing, from $71.4 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $388.6 million in Q2 2025 and troughed at $49.7 million in Q2 2022.
• A 5-year average of $99.1 million and a median of $72.1 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses sank 37.62% in 2024, then surged 360.43% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $124.9 million in 2022, then declined by 7.45% to $115.6 million in 2023, then fell by 18.94% to $93.7 million in 2024, then retreated by 23.8% to $71.4 million in 2025, then gained by 10.64% to $79.0 million in 2026.
• Business Quant data shows MYGN's Other Operating Expenses at $79.0 million in Q1 2026, $71.4 million in Q4 2025, and $71.0 million in Q3 2025.